Background: Sarcopenia has been associated with poor outcomes in patients with cirrhosis and solid tumours. Objective: Analyse the influence of sarcopenia on survival and treatment duration in patients with advanced hepatocellular carcinoma (HCC) treated with sorafenib. Methods: We conducted a multicentre, retrospective study on 96 patients with advanced HCC treated with sorafenib, all with available abdominal computed tomography (CT) scan within 30 days from treatment start. Anthropometric, laboratory, treatment and follow-up data were collected. Sarcopenia was defined by reduced skeletal muscle index calculated from an L3 section CT image. Results: Sarcopenia was present in 49% of patients. Patients were divided into two groups according to sarcopenia: age was significantly higher in the sarcopenic group (SG) (66 years (31-87) versus 72 years (30-84), p ¼ 0.04], with no difference in other baseline characteristics. The SG showed shorter overall survival (OS) (39 (95% confidence interval (CI) 26-50) versus 61 (95% CI 47-77) weeks (p ¼ 0,01)) and shorter time on treatment (12.3 (95% CI 8-19) versus 25.9 (95% CI 15-33) weeks (p ¼ 0.0044)). At multivariate analysis, sarcopenia was independently associated to reduced OS (p ¼ 0.03) and reduced time on treatment (p ¼ 0.001). Conclusion: Sarcopenia is present in almost half of patients with advanced HCC, and is associated with reduced survival and reduced duration of oral chemotherapy.
Introduction
Hepatocellular carcinoma (HCC) is the third cause of cancer related deaths, with rising incidence worldwide, with nearly 750,000 new cases per year. 1 Epidemiological data suggest that the incidence of HCC is still similar to the death rate, and thus almost all patients who are diagnosed with HCC will die because of it. 1 In developed countries, HCC predominantly affects the elderly, and is diagnosed at an advanced stage (Barcelona Clinic Liver Cancer (BCLC-C)) in up to 40% of all patients. 2 At this stage, the only approved treatment in Italy is sorafenib (Nexavar Õ , Bayer), an orally administered multikinase inhibitor shown to improve survival, but burdened by relatively high costs and toxicity rates, limiting patients' chances of receiving full dose treatment and hindering their quality of life. 3 Therefore, the search for prognostic tools able to stratify risk, predict toxicity and allow for therapy tailoring for each patient is of major clinical interest. 4 The condition of reduced muscle mass, defined as sarcopenia, 5, 6 has been identified as an independent predictor of reduced survival, tolerance to chemotherapy and higher rates of toxicity in patients with different neoplasias. [7] [8] [9] [10] In the research setting, imaging techniques such as computed tomography (CT) scanning are considered the gold standard for estimating muscle mass. 6 In the field of hepatology, sarcopenia has been linked to reduced survival rates in different therapeutic settings such as liver transplantation, hepatic resection and intra-arterial treatments for HCC. [11] [12] [13] [14] [15] Its presence has also been associated with increased toxicity in patients with HCC treated with sorafenib 16 and reduced survival, but the few data available come mainly from oriental series, where ethnic and anthropometric differences limit reproducibility in a Western setting. [17] [18] [19] Only one Western study is available, with a limited number of patients treated with various tyrosine kinase inhibitors. 20 The aim of the present study was to identify the prevalence and influence of sarcopenia in a homogeneous population of European Caucasian patients with advanced HCC undergoing sorafenib therapy.
We aimed to evaluate the influence of sarcopenia on patients' survival, as well as on the duration and tolerance of sorafenib treatment.
Materials and methods

Study design
This is a multicentre, retrospective study to assess the added value of sarcopenia evaluation in patients with advanced HCC and patients with an intermediate HCC who were not eligible for or failed ablative therapies, treated with sorafenib according to international guidelines. 2 Patients were followed and included in four different units in three hospital centres from 2008 to 2016.
Patients and data collection
All patients with advanced HCC, i.e. classified as BCLC stage C and those with a BCLC-B stage who were unfit to any or failed to respond to locoregional therapies, 2 were enrolled. HCC was diagnosed by the criteria of the American Association for the Study of Liver Disease 21 and staged by abdominal dynamic contrast-enhanced CT scan or gadolinium-enhanced magnetic resonance imaging (MRI). Each patient underwent also chest X-ray/CT scan and bone scanning as requested by the attending physicians.
The main inclusion criteria were those specified by the Italian Medicines Agency (AIFA) and the availability of an abdominal CT scan within 1 month before the start of sorafenib treatment. We analysed gender, age, pre-treatment anthropometric features, laboratory findings (including serum albumin, creatinine, international normality ratio (INR) and alpha-fetoprotein (AFP)), dry weight body mass index (BMI), macrovascular invasion and extra-hepatic spread. Cirrhosis, diagnosed either by histology or clinically, was graded according to the Child-Pugh and Model for End-stage Liver Disease (MELD) scores as a measures of liver impairment. 22, 23 Performance status (PS) was scored according to the Eastern Cooperative Oncology Group (ECOG). 24 All data were obtained within 1 month before the start of sorafenib treatment. Follow-up was ended at patients' death, last visit or on 10 December 2016.
After initial data collection, all patients were given an identification number to guarantee anonymity and information was entered in a dedicated database for statistical analysis. All patients gave informed consent for the use of clinical, laboratory and radiological data at the time of the first examination. The study protocol conforms to the ethical guidelines of the 1975 Declaration of Helsinki and was approved by local the institutional review board (Comitato Etico Milano Area 2, Universita`degli Studi di Milano, 3 December 2017).
Image analysis and treatment modality
CT scans were obtained routinely at baseline for tumour staging purposes within 1 month prior to initiation of sorafenib treatment and used to determine the skeletal muscle index (SMI). A transverse image at the level of the third lumbar vertebrae (L3) was selected from each scan. Muscles at this level include psoas, erector spinae, quadratus lumborum, transversus abdominis, external and internal obliques, and the rectus abdominis. 10, 13, 25 Images were analysed with SliceOmatic V 5.0 software (Tomovision, Montreal, Quebec, Canada), which enables specific tissue selection by using previously determined Hounsfield units (HU). Skeletal muscle is selected and quantified by thresholds between -29 to þ150 HU. 26 These specific thresholds permit evaluation of skeletal muscle regardless of ascites in patients with cirrhosis, excluding muscular fat infiltration in the selected section. All CT images were analysed by two trained observers (GA and PB). Crosssectional areas were calculated and normalized for height (cm 2 /m 2 ) as reported elsewhere. 27 The MRI imaging data were excluded to avoid methodological heterogeneity. L3 SMI was expressed in cm 2 Sorafenib treatment was administered according to guidelines. Therapy was discontinued whenever the patient developed unacceptable toxicity, when radiological or symptomatic progression of HCC occurred, or by investigator's judgment of the patient being unlikely to beneEt from further treatment with sorafenib. Tumour progression was deEned either radiologically by modiEed response evaluation criteria in solid tumours (mRECIST) 28 or clinically in terms of worsening of PS or onset of symptoms unrelated to liver failure. 29 Another reason for treatment discontinuation was unacceptable treatment toxicity, i.e. grade 2-4 adverse events (AEs) not responding to dose reductions and/or temporary interruption of treatment as suggested by the manufacturer. 24, 30 Toxicity was assessed in all patients who received at least one dose of sorafenib; AEs were graded according to the National Cancer Institute's Common Terminology Criteria (version 3.0). 31 
Statistical analysis
Patients were divided in two groups according to the presence of sarcopenia and characteristics of the two groups were then compared. Continuous data were reported as mean AE SD or as median (range) and compared using a Student's t-test or Mann-Whitney test as appropriate. Categorical variables were expressed as number (percentage) and compared using the 2 test with Fisher's exact test, with Yates' correction as appropriate. Survival curves were estimated using the Kaplan-Meier method and compared using the logrank test. Overall survival (OS) time was defined as the period between treatment start and patient death, and the time on treatment was intended as time from treatment beginning to its end. Univariate analyses were performed using Cox's proposal hazards model and hazard ratios (HRs) of independent predictive factors were obtained. The variables significantly associated with endpoints in univariate analysis were entered in a sex-and age-adjusted multivariate model. All p-values were two sided and the level of significance was set at p < 0.05. Results are reported as HR and 95% confidence interval (CI). All statistical analyses were carried out on MedCalc Õ 12.5 statistical software. Data are expressed as percentage (number/total) median (range) for demographic and laboratory data in tables and text unless otherwise indicated.
Results
Clinical and biochemical characteristics of advanced HCC patients treated with sorafenib
Of the 119 initial patients selected for the study, 15 patients were excluded since they had only a baseline MRI available, 4 were excluded since CT imaging and/or required clinical/laboratory data were missing, and 4 patients were excluded since treatment was administered in an off-label schedule. Therefore, 96 Caucasian patients treated with sorafenib were included in the final analysis: 75 were men (78%), with a median age of 69 years (30-87); 21 patients were female (22%), all post-menopausal. The most prevalent cause of cirrhosis was chronic viral infection (hepatitis C virus and hepatitis B virus, 62%), while alcohol abuse ranked second (17%). Other baseline characteristics are summarized in Table 1 . 
Lumbar SMI and sarcopenia distribution
Factors influencing survival in advanced HCC patients treated with sorafenib
Overall survival in our cohort was 50 (3.1-298.1) weeks. According to the Kaplan-Meier method, median OS was significantly shorter among sarcopenic patients (63 versus 32 weeks, HR 1.69, p ¼ 0.02) (Figure 1) .
By univariate Cox analysis, factors associated with an increased mortality after sorafenib treatment were bilirubin level (p ¼ 0.02; HR 1.75) (cut-off 1.4 mg/dL), vascular invasion (p ¼ 0.03; HR 1.76), MELD (p ¼ 0.01; HR 1.08) and sarcopenia defined by L3 SMI (p ¼ 0.01; HR 1.71), while male gender, age, BMI, presence of ascites, INR, AFP, creatinine, albumin, sodium and Child-Pugh score were not associated with a higher mortality rate. In sex-and age-adjusted multivariate analysis using a Cox regression model (bilirubin was not entered to avoid colinearity with MELD score), the only independent factor significantly associated with an increased mortality was sarcopenia (p ¼ 0.03; HR 1.63). Univariate and multivariate analyses for OS are shown in Table 3 . 
Discussion
To the best of our knowledge, this is the largest multicentre study addressing the relationship between sarcopenia and survival in a homogeneous cohort of European Caucasian cirrhotic patients with advanced HCC treated with sorafenib. Our study indicates that sarcopenia is present in almost half of cirrhotic patients Bilirubin, creatinine and albumin were not included in the multivariate analysis to avoid colinearity, since they were included in either the Child-Pugh or MELD scores.
with advanced HCC selected to undergo sorafenib treatment. In our cohort, sarcopenia was independently associated with a twofold risk of mortality and reduced treatment duration, and inclusion of its measurement at baseline could be associated with an improvement in the prediction of mortality in patients with advanced HCC. Available data demonstrate that sarcopenia is commonly observed among patients with cirrhosis and associated with significant morbidity and mortality, contributing to reduced quality of life. Among cancer patients, prevalence of pre-therapeutic sarcopenia was found to be 38.6% in a recent comprehensive review of 32 studies. 32 In our population of cirrhotic patients with advanced HCC, the prevalence of sarcopenia, as derived by a measurable and reproducible technique, was even higher, probably due to the association of advanced stage cancer and underlying liver disease. This percentage is in line with those observed among HCC cirrhotic patients and in our previous paper in Caucasian patients with HCC using similar L3 SMI thresholds. 11, 15 As expected, sarcopenia was linked to gender and age. A paper from Japan previously reported a higher prevalence of sarcopenia in patients treated with sorafenib (close to 65%), probably linked to different thresholds chosen from Asian series published in the literature, and as suggested by the authors, could be unfit for Caucasian patients. 17 At odds with oriental data, sarcopenia was less represented in our patients, further suggesting a role of ethnicity in influencing results in this setting.
Unexpectedly, sarcopenia was more prevalent in female patients, a discordant result when compared to most of the available literature. Our finding may be due to the homogeneous composition of our cohort, which was comprised exclusively of patients of CaucasianMediterranean origin, again suggesting a possible role of ethnicity in determining the development of sarcopenia, and to the generalized post-menopausal state of our female patients, as it is well known that the protective effect of oestrogens in counteracting sarcopenia development is lost after menopause. 33 Sarcopenia measurement can be obtained at marginally increased costs from CT scans already available at baseline for staging purposes, providing a further independent prognostic index to plan appropriate patient management. Furthermore, the dedicated software used overcomes the intrinsic limits of bioimpedance and anthropometric measurement, hampered by elevated BMI and ascites. 6, 34, 35 In addition, since the measurements we performed were not limited to the psoas only, but comprised all the muscles represented in the transverse image selected, it maximized the opportunity to obtain a representative sample of muscle mass.
Sarcopenic patients experienced more serious AEs and remained on treatment for a shorter period of time, which suggests that sarcopenia could assist in performance status evaluation, normally applied to HCC patients for staging and treatment allocation. 2 The role of reduced muscle mass in exposing patients to an increased risk of developing sorafenib-related side effects has been reported in a previous study. 16 Our study, conducted in a larger and homogeneous sample representative of advanced HCC, including different degrees of liver functional reserve and performance status, confirms and completes these findings.
An additional relevant finding of our study is that sarcopenia was prevalent in 49% of overweight/obese patients (BMI ! 25). This observation confirms the warning that sarcopenia is not exclusively to be sought in patients with low BMI, strengthening the importance and prevalence of sarcopenic obesity. 10, 11, 15 Our data further contributes to the definition of the role of sarcopenia as a possible predictor of reduced survival and cancer treatment toxicity, as has been previously shown in other oncological settings. 10 Accurate measurement tools are also needed in HCC, and CTbased technologies provide measurable and repeatable muscle mass measurement. We believe that sarcopenia assessment can certainly be an additional component in the complex decision-making process surrounding therapeutic choices in advance HCC.
The main limitation of our study is the retrospective design, which cannot exclude selection bias, that was nonetheless minimized by cross-referencing clinical and radiological databases, and the unavailability of full data regarding sorafenib initial dose and dose reduction.
In conclusion, our data show that European Caucasian cirrhotic patients with advanced HCC have a high prevalence of sarcopenia, and that its measurement by CT scan could be a readily available tool to identify them, improving prognostic evaluation at minimally increased costs.
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